Apogee Therapeutics Inc (APGE) — Smart Money Tracker (13F, Q2 2026)

APGE ranks #2176 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

APGE is a top-conviction position for Venrock Adviser, LLC — at 34.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Venrock Adviser, LLC has added to its APGE position for two straight quarters, increasing it by $486.2M to reach $1.1B today.

JPMorgan has trimmed its APGE position for two straight quarters, cutting it by $55.7M while still holding $47.9M.

APGE is down 0% today, but institutions show net buying of $441.3M this quarter — a divergence between today's price move and the underlying institutional flow.

APGE reported a net loss of $255.8M in its latest fiscal year.

• Not yet profitable — net loss of $255.8M in the latest fiscal year
• Net income declined year over year, from -$182.1M to -$255.8M
• Operating cash flow was negative, using $227.5M in cash
• Current ratio of 26.57x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range